Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

organon belgium bv-srl - etonogestrel 11,7 mg; ethinylestradiol 2,7 mg - vaginal delivery system - 0,120 mg/24 h - 0,015 mg/24 h - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - vaginal ring with progestogen and estrogen

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet - excipient ingredients: maize starch; magnesium stearate; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

organon belgium bv-srl - ethinylestradiol 2,7 mg; etonogestrel 11,7 mg - vaginal delivery system - 0,120 mg/24 h - 0,015 mg/24 h - etonogestrel 11.7 mg; ethinylestradiol 2.7 mg - vaginal ring with progestogen and estrogen

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - etonogestrel 11,7 mg; ethinylestradiol 2,7 mg - vaginal delivery system - 0,120 mg/24h - 0,015 mg/24h - etonogestrel 11.7 mg; ethinylestradiol 2.7 mg - vaginal ring with progestogen and estrogen

Malta - English - Medicines Authority

focused pharma ltd 37, geronimo abos street, iklin ikl 1022, malta - etonogestrel, ethinylestradiol - vaginal delivery system - ethinylestradiol 3.474 mg etonogestrel 11 mg - other gynecologicals

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aspen medical products malaysia sdn bhd - desogestrel; ethinylestradiol; desogestrel; ethinylestradiol -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - bella is indicated for use:,? as an oral contraceptive.,? for the treatment of moderate acne vulgaris in women who seek oral contraception.,? for the treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of ethinylestradiol/drospirenone 20 microgram/3 mg tablets for pmdd was not assessed beyond 3 cycles. ethinylestradiol/drospirenone 20 microgram/3 mg tablets have not been evaluated for treatment of pms (premenstrual syndrome) (see section 5.1 pharmacodynamic properties ? clinical trials).